VivaCell-MTS continues to support the National Center for Oncology

With the support of VivaCell-MTS, the National Center for Oncology has purchased a state of the art ultrasonic diagnostic device “Xario 200”, which is endowed with necessary transmitters for vascular duplex scanning and myocardial ultrasound examinations.

The company has allocated AMD 25mln to purchase the device.

“The aim of our cooperation with this center is important: the medical tests done with modern medical equipment will enable the specialists to understand the problem more clearly and outline the best course of treatment. I believe the time will come when this disease will be moved out from the list of incurable diseases”, stated VivaCell-MTS General Manager Ralph Yirikian.

Annually, over 10 thousand people with various tumor diseases are treated at the National Center for Oncology. Around 3200 patients are operated, around 4500 get antineoplastic chemotherapy and around 1500 patients get radiation treatment annually

Since 2010, VivaCell-MTS has made a total investment of more than AMD 115mln to equip the Center with the state of the art equipment.